DE60223720D1 - Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5 - Google Patents
Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5Info
- Publication number
- DE60223720D1 DE60223720D1 DE60223720T DE60223720T DE60223720D1 DE 60223720 D1 DE60223720 D1 DE 60223720D1 DE 60223720 T DE60223720 T DE 60223720T DE 60223720 T DE60223720 T DE 60223720T DE 60223720 D1 DE60223720 D1 DE 60223720D1
- Authority
- DE
- Germany
- Prior art keywords
- modulators
- heteroaryl
- glutamate receptor
- metabotropic glutamate
- substituted pyrazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34138201P | 2001-12-18 | 2001-12-18 | |
US341382P | 2001-12-18 | ||
PCT/US2002/040147 WO2003051833A2 (en) | 2001-12-18 | 2002-12-13 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60223720D1 true DE60223720D1 (de) | 2008-01-03 |
DE60223720T2 DE60223720T2 (de) | 2008-10-30 |
Family
ID=23337314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60223720T Expired - Lifetime DE60223720T2 (de) | 2001-12-18 | 2002-12-13 | Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7569592B2 (de) |
EP (1) | EP1458383B1 (de) |
JP (1) | JP4286146B2 (de) |
AU (1) | AU2002359714B2 (de) |
CA (1) | CA2469813C (de) |
DE (1) | DE60223720T2 (de) |
ES (1) | ES2295441T3 (de) |
WO (1) | WO2003051833A2 (de) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60227794D1 (de) * | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
ATE486600T1 (de) * | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP1613614A2 (de) * | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | Diarylsubstituierte pyrazolmodulatoren des metabotropen glutamatrezeptors-5 |
WO2004087653A2 (en) * | 2003-04-03 | 2004-10-14 | Merck & Co., Inc. | 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 |
CA2537141A1 (en) * | 2003-09-02 | 2005-03-10 | Merck And Co., Inc. | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 |
AU2005215379A1 (en) * | 2004-02-12 | 2005-09-01 | Merck & Co., Inc. | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
US20070197549A1 (en) * | 2004-02-18 | 2007-08-23 | Astrazeneca Ab | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists |
AU2005219791B2 (en) * | 2004-03-05 | 2011-06-09 | Msd K.K. | Diaryl-substituted five-membered heterocycle derivative |
AU2005223483B2 (en) | 2004-03-18 | 2009-04-23 | Zoetis Llc | N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides |
EP2305352A1 (de) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-Reduktaseinhibitoren zur Behandlung von Stoffwechsel- und anthropometrischen Störungen |
EP1812071A2 (de) | 2004-10-13 | 2007-08-01 | PTC Therapeutics, Inc. | Verbindungen zur nonsense-unterdrückung und verwendung dieser verbindungen für die herstellung eines medikaments zur behandlung somatischer mutationsbedingter erkrankungen |
DE102008020113A1 (de) | 2008-04-23 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dihydropyrazolone und ihre Verwendung |
AU2005322173A1 (en) * | 2004-12-27 | 2006-07-06 | Astrazeneca Ab | Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders |
TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
AU2006227729B2 (en) * | 2005-03-16 | 2011-10-13 | Aventis Pharmaceuticals Inc. | Dipyrazoles as central nervous system agents |
DE102005019712A1 (de) | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
CA2609783A1 (en) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss |
EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US7951824B2 (en) * | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007223036A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2026813A2 (de) * | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5-ht-rezeptor-vermittelte neurogenese |
EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
US7998971B2 (en) * | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
EP2066355A2 (de) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Kombination aus einem durch einen peroxisom-proliferator aktivierten rezeptor-mittel und einem zweiten neurogenen mittel zur behandlung von erkrankungen des nervensystems sowie zur förderung von neuraler differenzierung und neurogenese |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
DE102006050515A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
DE102006050513A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substitiuierte Dihydropyrazolone und ihre Verwendung |
CA2687306A1 (en) | 2007-05-18 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
MX2010002266A (es) * | 2007-08-30 | 2010-03-25 | Takeda Pharmaceutical | Derivados de pirazol sustituidos. |
EP3239170B1 (de) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase |
EP3241839B1 (de) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase |
KR20110092266A (ko) | 2008-08-04 | 2011-08-17 | 씨에이치디아이 파운데이션, 인코포레이티드 | 소정 키누레닌-3-모노옥시게나아제 억제제, 약학적 조성물, 및 그의 사용 방법 |
EP2352725A1 (de) * | 2008-11-07 | 2011-08-10 | Wyeth LLC | Lxr-modulatoren auf chinoxalinbasis |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
CN102573478B (zh) * | 2009-10-12 | 2015-12-16 | 拜尔农作物科学股份公司 | 作为杀虫剂的1-(吡啶-3-基)-吡唑和1-(嘧啶-5-基)-吡唑 |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
US9090632B2 (en) * | 2010-08-31 | 2015-07-28 | Vanderbilt University | Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mGluR5 receptors |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
DE102010044131A1 (de) | 2010-11-18 | 2012-05-24 | Bayer Schering Pharma Aktiengesellschaft | Substituiertes Natrium-1H-pyrazol-5-olat |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
CA2818903C (en) | 2010-12-14 | 2021-03-23 | Electrophoretics Limited | 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor |
BR112014004845A2 (pt) | 2011-08-30 | 2017-04-04 | Chdi Foundation Inc | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada |
CN106518845B (zh) | 2011-08-30 | 2019-09-13 | Chdi基金会股份有限公司 | 犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法 |
UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8642774B2 (en) | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
US8796467B2 (en) | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
US8716277B2 (en) | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
US8883789B2 (en) | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8937176B2 (en) | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
ES2638144T3 (es) | 2011-12-21 | 2017-10-18 | Bayer Intellectual Property Gmbh | Bencilpirazoles sustituidos |
US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
EP2914587A1 (de) * | 2012-10-31 | 2015-09-09 | Bayer CropScience AG | Neue heterocylische verbindungen als schädlingsbekämpfungsmittel |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
GB201312800D0 (en) | 2013-07-17 | 2013-08-28 | Heptares Therapeutics Ltd | mGlu5 modulators |
HUE053654T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR- és CMET-inhibitorok kombinációi a rák kezelésére |
JP6980385B2 (ja) | 2014-03-26 | 2021-12-15 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | Fgfr阻害剤とigf1r阻害剤の組合せ |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
WO2015161014A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
DK3152199T3 (en) | 2014-06-03 | 2018-11-26 | Idorsia Pharmaceuticals Ltd | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS |
SG11201700341PA (en) | 2014-07-17 | 2017-02-27 | Chdi Foundation Inc | Methods and compositions for treating hiv-related disorders |
AU2015317022B2 (en) | 2014-09-15 | 2020-01-16 | Idorsia Pharmaceuticals Ltd | Triazole compounds as T-type calcium channel blockers |
KR20170049604A (ko) | 2014-09-19 | 2017-05-10 | 바이엘 파마 악티엔게젤샤프트 | Bub1 억제제로서의 벤질 치환된 인다졸 |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
KR20180052631A (ko) | 2015-09-23 | 2018-05-18 | 얀센 파마슈티카 엔.브이. | 비-헤테로아릴 치환된 1,4-벤조디아제핀 및 암의 치료를 위한 이의 용도 |
BR112018005637B1 (pt) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos |
CA3046846A1 (en) | 2016-12-16 | 2018-06-21 | Idorsia Pharmaceuticals Ltd | Pharmaceutical combination comprising a t-type calcium channel blocker |
TWI808960B (zh) | 2017-02-06 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 用於合成1-芳基-1-三氟甲基環丙烷之新穎方法 |
KR20210033503A (ko) * | 2018-07-18 | 2021-03-26 | 아르커스 바이오사이언시즈 인코포레이티드 | 아졸로피리미딘 화합물의 고체 형태 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2833779A (en) * | 1956-10-29 | 1958-05-06 | American Cyanamid Co | Substituted pyrazoles |
US5859215A (en) * | 1995-10-25 | 1999-01-12 | Wallac Oy | Biospecific binding reactants labelled with luminescent lanthanide chelates and their use |
US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
DK1210344T3 (da) * | 1999-08-19 | 2006-03-06 | Nps Pharma Inc | Heteropolycykliske forbindelser og anvendelser deraf som metabotrope glutamatreceptorantagonister |
WO2003029210A2 (en) * | 2001-10-04 | 2003-04-10 | Merck & Co. Inc. | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
AU2002365892A1 (en) * | 2001-11-30 | 2003-06-17 | Merck & Co., Inc. | Metabotropic glutamate receptor-5 modulators |
CA2469821C (en) * | 2001-12-18 | 2009-10-20 | Merck & Co., Inc. | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 |
JP4357965B2 (ja) * | 2001-12-21 | 2009-11-04 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピロールモジュレーター |
ATE486600T1 (de) * | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5 |
WO2004087653A2 (en) * | 2003-04-03 | 2004-10-14 | Merck & Co., Inc. | 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 |
EP1613614A2 (de) * | 2003-04-03 | 2006-01-11 | Merck & Co., Inc. | Diarylsubstituierte pyrazolmodulatoren des metabotropen glutamatrezeptors-5 |
WO2004089308A2 (en) * | 2003-04-04 | 2004-10-21 | Merck & Co., Inc. | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 |
US7268151B2 (en) * | 2003-04-04 | 2007-09-11 | Merck & Co., Inc. | Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 |
CA2537141A1 (en) * | 2003-09-02 | 2005-03-10 | Merck And Co., Inc. | Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 |
US20060189661A1 (en) * | 2003-11-03 | 2006-08-24 | Wagenen Bradford V | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
AU2005215379A1 (en) | 2004-02-12 | 2005-09-01 | Merck & Co., Inc. | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
WO2007070563A2 (en) * | 2005-12-13 | 2007-06-21 | Harkness Pharmaceuticals, Inc. | Stable solid forms of enterostatin |
-
2002
- 2002-12-13 ES ES02794267T patent/ES2295441T3/es not_active Expired - Lifetime
- 2002-12-13 WO PCT/US2002/040147 patent/WO2003051833A2/en active IP Right Grant
- 2002-12-13 US US10/497,122 patent/US7569592B2/en active Active
- 2002-12-13 CA CA002469813A patent/CA2469813C/en not_active Expired - Fee Related
- 2002-12-13 EP EP02794267A patent/EP1458383B1/de not_active Expired - Lifetime
- 2002-12-13 AU AU2002359714A patent/AU2002359714B2/en not_active Ceased
- 2002-12-13 DE DE60223720T patent/DE60223720T2/de not_active Expired - Lifetime
- 2002-12-13 JP JP2003552720A patent/JP4286146B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20050026963A1 (en) | 2005-02-03 |
WO2003051833A3 (en) | 2003-10-30 |
EP1458383A4 (de) | 2005-05-25 |
US7569592B2 (en) | 2009-08-04 |
WO2003051833A2 (en) | 2003-06-26 |
ES2295441T3 (es) | 2008-04-16 |
CA2469813C (en) | 2009-02-24 |
AU2002359714A1 (en) | 2003-06-30 |
DE60223720T2 (de) | 2008-10-30 |
AU2002359714B2 (en) | 2006-12-21 |
CA2469813A1 (en) | 2003-06-26 |
JP4286146B2 (ja) | 2009-06-24 |
EP1458383A2 (de) | 2004-09-22 |
EP1458383B1 (de) | 2007-11-21 |
JP2005516934A (ja) | 2005-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60223720D1 (de) | Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5 | |
EP1453815A4 (de) | Modulatoren des metabotropen glutamatrezeptors-5 | |
ZA200501101B (en) | Oxadiazoles as modulators of metabotropic glutamate receptor-5. | |
EP1458385A4 (de) | Heteroaryl-substituierte imidazol-modulatoren des metabotropen glutamat-rezeptors-5 | |
ATE369330T1 (de) | O-desmethyl-venlafaxine succinat salz | |
DE60325025D1 (de) | Modulatoren des vanilloidrezeptors | |
ATE451348T1 (de) | N-(3-amino-2-hydroxy-propyl)substituierte alkylamidverbindungen | |
EP1458710A4 (de) | Heteroarylsubstituierte pyrrolmodulatoren des metabotropen glutamatrezeptors 5 | |
DE60239146D1 (de) | Neue kristalline verbindung | |
IL166510A0 (en) | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 | |
DK1563100T3 (da) | Fortrængningssandwich-immuno-PCR | |
NO20041767L (no) | Pyrrolidinonderivater | |
NO20023677L (no) | Sementeringsmanifold-enhet | |
DE60219284D1 (de) | Dreischichtige maschenware | |
EP1613617A4 (de) | Diarylsubstituierte triazolmodulatoren des metabotropen glutamatrezeptors-5 | |
EP1613265A4 (de) | Di-aryl-substituierte pyrrol-modulatoren von metabotropischem glutamat-rezeptor-5 | |
ATE335740T1 (de) | Ringannelierte pyrazolderivate | |
DE60221187D1 (de) | Bandraupe | |
DE60201256D1 (de) | Elektrooptischer wanderwellenmodulator | |
DK1483451T3 (da) | Betonblok | |
ATE346045T1 (de) | Heteroaryl-substituierte aminocyclohexan-derivate | |
FI20010129A0 (fi) | Kaksiviiraformeri | |
FI5259U1 (fi) | Kehto | |
DE60211574D1 (de) | Seriendruckgerät | |
ATA5002002A (de) | Vibrator |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: MERCK & CO., INC., RAHWAY, N.J., US |
|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: MERCK SHARP & DOHME CORP., RAHWAY, N.J., US |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LUXEMBOURG, LU |
|
R081 | Change of applicant/patentee |
Ref document number: 1458383 Country of ref document: EP Owner name: SCHERING CORPORATION, US Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., RAHWAY, US Effective date: 20121213 |
|
R082 | Change of representative |
Ref document number: 1458383 Country of ref document: EP Representative=s name: MARKS & CLERK (LUXEMBOURG) LLP, LU Effective date: 20121213 |